Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.51 |
| ▸ | SCN4A | P35499 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067290 | 0.79 | PTGDR2 (0.51) | PTGDR2SCN4ANOS2CYP2C9CYP1A2 | |
| SCHEMBL16150998 | 0.78 | PTGDR2 (0.53) | PTGDR2SLC9A1SLC6A9 | |
| SCHEMBL2065925 | 0.76 | PTGDR2 (0.46) | PTGDR2PTGER1FFAR1FFAR4PPARA | |
| SCHEMBL29772176 | 0.75 | PTGDR2 (0.60) | PTGDR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL27524115 | 0.75 | PTGDR2 (0.60) | PTGDR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL11619019 | 0.74 | PTGDR2 (0.56) | PTGDR2SCN4ACYP2C9PTGER1FFAR1 | |
| Hydrochloric Acid SCHEMBL11620952 | 0.73 | NOS2 (0.64) | PTGDR2NOS2 | |
| SCHEMBL2795889 | 0.73 | PTGDR2 (0.58) | PTGDR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2795887 | 0.73 | PTGDR2 (0.58) | PTGDR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL11619688 | 0.73 | PTGDR2 (0.63) | PTGDR2CYP2C9PTGER1FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507551-B2 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-13 | — | — | US | claimed |
| US-20090042976-A1 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIS (US) | 2009-02-12 | — | — | US | claimed |
| US-8778913-B2 | Antimicrobial compositions for treating microbial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140154302-A1 | ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | THE UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (US) | 2014-06-05 | — | — | US | disclosed |
| US-8507551-B2 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-13 | — | — | US | disclosed |
| US-8148352-B2 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090306021-A1 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090042976-A1 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIS (US) | 2009-02-12 | — | — | US | disclosed |
| EP-2020857-A2 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | The Regents of the University of California (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007133712-A2 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306021-A1 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | SERPINB1, CUTA, SRRT | PTGDR2 3898/4885SCN4A 3635/4885NOS2 1004/4885 |
| US-20140154302-A1 | ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | MPO, CUTA, STING1 | PTGDR2 3623/4885SCN4A 4451/4885NOS2 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.